CBU
RXRX icon

CIBC Bancorp USA’s Recursion Pharmaceuticals RXRX Stock Holding History

CIBC Bancorp USA’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
28,405
+5,320
+23% +$17.7K ﹤0.01% 1851
2026
Q1 		$70.9K Buy
+23,085
New +$89.2K ﹤0.01% 1702
2025
Q3 		$191K Buy
+39,098
New +$205K ﹤0.01% 1275

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

CIBC Bancorp USA's RXRX Position: Q2 2026 in Review

CIBC Bancorp USA increased its Recursion Pharmaceuticals (RXRX) stake by 23% in Q2 2026, buying an estimated $17.7K and bringing the position to 28,405 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #1851.

CIBC Bancorp USA first reported a position in RXRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $191K in Q3 2025. 320 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • CIBC Bancorp USA held 28,405 shares of Recursion Pharmaceuticals worth $104K as of Q2 2026.
  • CIBC Bancorp USA bought 5,320 Recursion Pharmaceuticals shares in Q2 2026, an estimated $17.7K.
  • Recursion Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1851 holding.
  • CIBC Bancorp USA first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's Recursion Pharmaceuticals position peaked at $191K in Q3 2025.
  • 320 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.